|
End-of-day quote
Buenos Aires S.E.
02/11/2026
|
5-day change | 1st Jan Change | ||
| 70,525.00 ARS | -0.84% |
|
+6.01% | +50.50% |
| 11-03 | Dr Reddy's gets tentative US FDA nod for generic HIV prevention | RE |
| 10-31 | Gilead's HIV Franchise Supports Growth Outlook, RBC Says | MT |
| Market Cap | 211B 326,175B 189B 173B 157B 295B 20,001B 301B 2,067B 833B 10,557B 793B 776B 33,344B | P/E 2026 * |
-40.8x | P/E 2027 * | 20.6x |
|---|---|---|---|---|---|
| Enterprise Value | 233B 359,017B 208B 191B 173B 325B 22,015B 331B 2,276B 917B 11,620B 873B 854B 36,701B | EV / Sales 2026 * |
7.43x | EV / Sales 2027 * | 6.64x |
| Free-Float |
99.86% | Yield 2026 * |
1.94% | Yield 2027 * | 1.98% |
| Markets | Quality | ||
|---|---|---|---|
Buenos Aires S.E.
| GILD | End-of-day quote | |
Buenos Aires S.E.
| GILDD | End-of-day quote |
Last Transcript: Gilead Sciences, Inc.
| 1 day | -0.84% | ||
| 1 week | +6.01% | ||
| Current month | -0.84% | ||
| 1 month | +20.04% | ||
| 3 months | +37.14% | ||
| 6 months | +43.64% | ||
| Current year | +50.50% |
| 1 week | 64,800 |  | 72,400 |
| 1 month | 57,325 | | 72,400 |
| Current year | 44,320 | | 72,400 |
| 1 year | 43,220 | | 72,400 |
| 3 years | 15,000 | | 72,400 |
| 5 years | 2,682.5 | | 72,400 |
| 10 years | 656.5 | | 72,400 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.84% | +6.01% | - | - | 211B | |
| -0.46% | +10.31% | +63.52% | +143.15% | 1,257B | |
| -0.97% | +1.60% | +43.25% | +80.09% | 651B | |
| -2.05% | +0.73% | +32.47% | +101.62% | 510B | |
| -0.37% | -0.73% | +52.64% | +66.95% | 388B | |
| -0.78% | +5.51% | +72.55% | +44.25% | 366B | |
| +0.64% | +2.83% | +33.09% | +58.89% | 303B | |
| -0.12% | +7.96% | +11.95% | +34.78% | 288B | |
| -0.12% | +4.68% | +55.97% | +74.59% | 252B | |
| -0.21% | +7.34% | +42.19% | +109.69% | 211B | |
| Average | -0.44% | +4.59% | +45.29% | +79.34% | 469.63B | |
| Weighted average by Cap. | -0.58% | +5.30% | +49.22% | +93.67% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 31.29B 48,307B 27.93B 25.63B 23.32B 43.72B 2,962B 44.59B 306B 123B 1,563B 117B 115B 4,938B | 33.55B 51,797B 29.95B 27.49B 25B 46.88B 3,176B 47.81B 328B 132B 1,676B 126B 123B 5,295B |
| Net income | -5.09B -7,859B -4.54B -4.17B -3.79B -7.11B -482B -7.25B -49.81B -20.08B -254B -19.11B -18.7B -803B | 10.61B 16,378B 9.47B 8.69B 7.91B 14.82B 1,004B 15.12B 104B 41.84B 530B 39.81B 38.96B 1,674B |
| Net Debt | 21.27B 32,842B 18.99B 17.43B 15.85B 29.72B 2,014B 30.31B 208B 83.91B 1,063B 79.84B 78.13B 3,357B | 11.61B 17,927B 10.37B 9.51B 8.65B 16.22B 1,099B 16.55B 114B 45.8B 580B 43.58B 42.65B 1,833B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/11/26 | ARS 70,525.00 | -0.84% | 572 |
| 30/10/26 | ARS 71,125.00 | +4.67% | 5,087 |
| 29/10/26 | ARS 67,950.00 | +3.07% | 569 |
| 28/10/26 | ARS 65,925.00 | +0.38% | 196 |
| 27/10/26 | ARS 65,675.00 | -1.28% | 62 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD Stock
Select your edition
All financial news and data tailored to specific country editions
